Day One Biopharmaceuticals (DAWN) sold its Priority Review Voucher for $108M to an undisclosed buyer. The Company was awarded the PRV following the U.S. Food and Drug Administration accelerated approval of OJEMDA. As part of the transaction, $8.1M of the total consideration received from the sale of the PRV will be paid to Viracta Therapeutics (VIRX) to fully satisfy PRV related obligations of the Company’s license agreement with Viracta, dated December 16, 2019, as amended.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One Announces Sale of Priority Review Voucher for $108 Million
- BrightSpring Health announces Onco360 selected as partner for OJEMDA
- Day One price target lowered to $40 from $50 at H.C. Wainwright
- Day One Biopharmaceuticals reports Q1 EPS (72c), consensus (66c)
- Day One Biopharmaceuticals Unveils Updated Corporate Presentation
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue